The importance of testing Covid-19 tests
The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
Abbott’s speedy Covid-19 test comes under fire
Abbott’s coronavirus RNA test can ID NOW – but maybe not definitively.
Another knock for the Celgene contingent value right
A week after one Bristol-Myers Squibb approval decision was delayed a second suffers a similar fate, and the group’s CVR slowly unravels.
Quidel wins the Covid-19 antigen test race
Antigen tests are faster and cheaper than viral RNA assays, but are notably less accurate.
Lynparza nod confirms a leg up for Glaxo
As the battle between Parp inhibitors for front-line ovarian cancer intensifies, biomarker testing and Avastin biosimilars will play a role.
Roche takes on Abbott in Covid-19 antibody testing
Robust specificity data mark Roche’s serological test out as a major competitor.
FDA authorises the first Covid-19 antibody test
Cellex wins the race to get the FDA’s buy-in for a blood test to pinpoint immunity.
Crisis, what crisis? Curevac denies everything
As a Covid-19 vaccine exclusivity and senior management storm engulfs Curevac, the German mRNA specialist insists it’s just conjecture and coincidence.
Few groups have developed Covid-19 diagnostics – but this will change
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
